Proto Oncogene Tyrosine Protein Kinase Src – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)- Pipeline Review, H2 2019’, provides in depth analysis on Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Respiratory, Musculoskeletal Disorders and Ophthalmology under development targeting Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)

– The report reviews Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics”

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“AbbVie Inc

AstraZeneca Plc

Boehringer Ingelheim International GmbH

Fratagene Therapeutics Srl

Lead Discovery Center GmbH

MAIA Biotechnology Inc

Onconova Therapeutics Inc

Prous Institute for Biomedical Research SA

TopiVert Ltd

Turning Point Therapeutics Inc”

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Overview 7

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 13

Products under Development by Universities/Institutes 17

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Therapeutics Assessment 19

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Companies Involved in Therapeutics Development 24

AbbVie Inc 24

Asana BioSciences LLC 24

AstraZeneca Plc 24

Boehringer Ingelheim GmbH 25

Lead Discovery Center GmbH 26

Onconova Therapeutics Inc 27

TopiVert Ltd 27

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Drug Profiles 28

AD-80 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

ASN-006 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

ilorasertib - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

JRP-890 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

nintedanib - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

ON-150030 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

saracatinib difumarate - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecules to Inhibit SRC for Oncology - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

TOP-1210 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

TOP-1288 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

TOP-1630 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

TOP-1890 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

TPX-0005 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Dormant Products 57

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Discontinued Products 59

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Product Development Milestones 60

Featured News & Press Releases 60

Nov 10, 2017: Results from six-month lung imaging study showed slowing of fibrotic progression in patients with IPF treated with Ofev versus placebo 60

Oct 23, 2017: Ofev demonstrates consistent long-term efficacy in IPF regardless of baseline lung function 60

Sep 11, 2017: Safety and efficacy results from the INJOURNEYTM trial investigating OFEV (nintedanib) with add-on pirfenidone provide new data to support nintedanib’s key role in IPF 62

Jul 19, 2017: Onyx helps accelerate TopiVert's compound to clinic 63

Jul 19, 2017: TopiVert Provides Update on TOP1630 64

Jun 27, 2017: TP Therapeutics Announces FDA Orphan Drug Designation Granted to TPX-0005 for Treatment of Non-Small Cell Lung Adenocarcinomas Harboring ALK, ROS1, or NTRK Oncogenic Rearrangements 64

Jun 05, 2017: Encouraging Phase II survival data for oral nintedanib in malignant pleural mesothelioma presented at ASCO 2017 65

May 24, 2017: IPF patients treated with OFEV (nintedanib) versus placebo were twice as likely to have improved or stable lung function 66

Apr 04, 2017: Onconova Therapeutics Announces Positive Preclinical Data on ON dual FLT3 and Src inhibitor 150030 at 2017 American Association of Cancer Research Annual Meeting 67

Mar 20, 2017: Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases 67

Dec 14, 2016: Nintedanib granted orphan drug designation for treatment of mesothelioma 68

Dec 07, 2016: Clinically meaningful data for oral nintedanib in mesothelioma presented at World Conference on Lung Cancer 68

Nov 28, 2016: TopiVert Receives IND Approval for TOP1630 in the Treatment of Dry Eye Syndrome 69

Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 69

Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 70

Appendix 72

Methodology 72

Coverage 72

Secondary Research 72

Primary Research 72

Expert Panel Validation 72

Contact Us 72

Disclaimer 73

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by AbbVie Inc, H2 2019

Pipeline by AstraZeneca Plc, H2 2019

Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Pipeline by Fratagene Therapeutics Srl, H2 2019

Pipeline by Lead Discovery Center GmbH, H2 2019

Pipeline by MAIA Biotechnology Inc, H2 2019

Pipeline by Onconova Therapeutics Inc, H2 2019

Pipeline by Prous Institute for Biomedical Research SA, H2 2019

Pipeline by TopiVert Ltd, H2 2019

Pipeline by Turning Point Therapeutics Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports